EFR3A

Across TCGA pan-cancer cohorts, EFR3A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EFR3A data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EFR3A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EFR3A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where EFR3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.595	0.946	<.001	40	view →
LSCC	DFS	Quartile	All	0.178	0.916	.006	11	view →
CCRCC	OS	Tertile	II,III,IV	1.000	0.212	.022	9	view →
LUAD	DFS	Quartile	II,III,IV	0.188	0.811	.016	3	view →
HNSC	OS	Quartile	II,III,IV	1.000	0.935	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EFR3A–PDAC (DFS)

Open the PDAC breakdown →